A gene therapy product approved for adults with hemophilia B may increase initial costs for health plans but can reduce expenditures by nearly $1 million over time, according to a recent study.
These savings could be magnified with 100% adoption of the product early on versus gradual uptake, the authors found (J Manag Care Spec Pharm 2024;30[8]:805-816).
To assess the impact of etranacogene dezaparvovec (Hemgenix, CSL Behring) on a commercial health plan budget, Songkai Yan of CSL